FINWIRES · TerminalLIVE
FINWIRES

Henlius Biotech Signs Deal With Sandoz for Up to 10 Biosimilars

By

Shanghai Henlius Biotech (HKG:2696) entered into a collaboration with Sandoz covering up to 10 biosimilar monoclonal antibody and antibody-drug conjugate products, according to a Monday Hong Kong bourse filing.

The first batch includes the cetuximab biosimilar HLX05-N, the evolocumab biosimilar HLX16, and a belimumab biosimilar.

Sandoz will receive the rights to develop, register, and commercialize the products globally, excluding mainland China, Hong Kong, Macau, and Taiwan, subject to product-specific terms.

Sandoz will pay up to $77 million in upfront payments, $160 million in development milestones, and $77 million in commercial milestones for the first batch, plus 40% of net sales or net profits in each country, unless otherwise agreed.

Related Articles

Asia

Sands China's Attributable Profit Slips 3.6% in H1; Interim Dividend Declared

Sands China (HKG:1928) recorded a 3.6% decline in profit attributable to equity holders in the first half to $398 million from $413 million a year prior.Earnings per share slipped to $0.0492 from $0.051 previously, according to a Friday Hong Kong bourse filing.Net revenue increased 11% to $3.88 billion from $3.49 billion in the year-ago period.The company declared an interim dividend of HK$0.50 per share for the period, payable Oct. 9 to shareholders of record as of Sept. 18.

HKG:1928
Asia

Longfor Warns of Lower H1 Profit

Longfor (HKG:0960) expects profit attributable to owners of between 1.8 billion yuan and 2 billion yuan for the six months ended June 30, down from 3.22 billion yuan a year prior.The property developer attributed the forecast to a continued decline in recognized revenue from the property development business and pressure on the recognized gross profit margin.

HKG:0960
Asia

MCC Logs 447.5 Billion Yuan in January-July New Contract Value

Metallurgical Corp. of China (SHA:601618, HKG:1618), or MCC's, newly-signed contract value for the seven months ended July 31 stood at around 447.5 billion yuan.Of the total, the value of newly-signed overseas contracts reached roughly 39.1 billion yuan, according to a Friday Hong Kong bourse filing.

HKG:1618SHA:601618